Oral oncology最新文献

{"title":"Survival rates and oncologic outcomes of adeno squamous carcinoma of oral cavity: A systematic review","authors":"Francesco Chiari ,&nbsp;Andrea Luigi Camillo Carobbio ,&nbsp;Marco Ferrari ,&nbsp;Piero Nicolai ,&nbsp;Claudio Donadio Caporale ,&nbsp;Pierre Guarino","doi":"10.1016/j.oraloncology.2025.107821","DOIUrl":"10.1016/j.oraloncology.2025.107821","url":null,"abstract":"<div><h3>Background</h3><div>Adenosquamous carcinoma (ASC) of the oral cavity is an uncommon and aggressive malignancy characterized by squamous and glandular histologic components. Due to its rarity, clinical behavior and oncologic outcomes remain poorly defined.</div></div><div><h3>Methods</h3><div>A systematic literature review was conducted according to PRISMA 2020 guidelines. Comprehensive searches of Embase, PubMed, Scopus, and Cochrane Library identified studies published between 1968 and 2025.</div></div><div><h3>Results</h3><div>Sixty-one patients were included. The most frequent subsites were tongue (43 %) and floor of mouth (31 %). Transoral surgery was performed in 93 % of cases, with neck dissection in 50 %. Adjuvant therapy was administered in 27 %. Despite 57 % presenting with early-stage disease, recurrence occurred in 42 %: local (36 %), regional (20 %), and distant (10 %). Local recurrence was significantly associated with advanced stage (p = 0.007) and subsite (p = 0.028), highest in floor of mouth (59 %) and gingiva (50 %). Perineural invasion (PNI), lymphovascular invasion (LVI), and positive margins correlated with recurrence and reduced time to recurrence (TTR), disease-specific survival (DSS), and overall survival (OS) (p &lt; 0.001). Two-year TTR, DSS, and OS rates were 47 %, 74 %, and 70 %, respectively—lower than reported for conventional oral squamous carcinoma. Because oral ASC is rare, the evidence is primarily derived from case reports and small retrospective series.</div></div><div><h3>Conclusions</h3><div>Oral ASC demonstrates high recurrence and poor survival, even in early-stage disease. Prognosis is strongly influenced by PNI, LVI, and margin status, as well as tumor subsite. These findings highlight oral ASC as a distinct and particularly aggressive entity.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107821"},"PeriodicalIF":3.9,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is 55 years an optimal age cutoff point for clinical staging in T1 papillary thyroid cancer?","authors":"Daixing Hu ,&nbsp;Zhuolin Dai ,&nbsp;Yang Feng ,&nbsp;Xinliang Su ,&nbsp;Chun Huang","doi":"10.1016/j.oraloncology.2025.107817","DOIUrl":"10.1016/j.oraloncology.2025.107817","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to determine the optimal age cutoff for T1 papillary thyroid cancer (PTC), with a particular focus on the T1a and T1b subgroups.</div></div><div><h3>Methods</h3><div>A retrospective review of electronic medical records was conducted to identify patients who underwent thyroidectomy at our institution from January 2013 to December 2018.</div></div><div><h3>Results</h3><div>The study cohort consisted of 2,862 patients, including 765 men (26.7 %) and 2,097 women (73.3 %). Survival analysis demonstrated significantly poorer recurrence-free survival (RFS) in patients aged ≥55 years (p &lt; 0.001). Patients were stratified into T1 (tumor size ≤2 cm, n = 2,328) and non-T1 (tumor size &gt;2 cm, n = 534) subgroups. Among the non-T1 subgroup, older patients exhibited significantly inferior RFS, consistent with the overall cohort (p &lt; 0.001). However, this difference was not observed in the T1 subgroup (p = 0.079). Within the T1 PTC subgroup, significant differences were identified between T1a and T1b patients concerning gender distribution, tumor size, clinical lymph node-positive status (cN1), total thyroidectomy, bilaterality, presence of Hashimoto’s thyroiditis, central lymph node metastasis, lateral lymph node metastasis, and radioiodine treatment (all p &lt; 0.05). Further analysis indicated that when stratified by an age cutoff of 65 years, the prognosis for T1b patients was statistically significant (p = 0.018), whereas the prognosis for T1a patients was not statistically significant (p = 0.64).</div></div><div><h3>Conclusion</h3><div>The clinicopathologic characteristics of T1b patients differ significantly from those of T1a patients. Age may not be a critical factor in the prognostic staging system for T1a PTC patients, whereas 65 years appears to be a more appropriate age cutoff for T1b patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107817"},"PeriodicalIF":3.9,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma: A nationwide, population-based study from the SweHNCR","authors":"A. Hafström ,&nbsp;E. Hammerlid ,&nbsp;M. Beran ,&nbsp;M. Olin ,&nbsp;A. Högmo ,&nbsp;L. Farnebo","doi":"10.1016/j.oraloncology.2025.107818","DOIUrl":"10.1016/j.oraloncology.2025.107818","url":null,"abstract":"<div><h3>Background and importance</h3><div>The major risk factor for vermilion lip squamous cell carcinoma (vlSCC) is excessive sunlight exposure. Population-based studies on treatment and outcome are lacking.</div></div><div><h3>Methods</h3><div>This is a nation-wide, population-based study of treatment and outcome from prospectively recorded data for 2,111 vlSCC registered in the Swedish Head and Neck Cancer Register (SweHNCR) diagnosed 2008–2022.</div></div><div><h3>Results</h3><div>The age standardized incidence increased with 34 % between 2008 and 2022, from 1.14 to 1.53 per 100,000 (19 % for males and 55 % for females). Median age at diagnosis was 76 years and 72.4 % had good performance status. Males predominated (57.1 %). Lower lip vlSCC comprised 82.6 % and upper 8.6 %. Most had T1 (81.7 %) or T2 (13.5 %) tumors and few had regional (2.7 %) or distant (0.1 %) metastases. The 5-year observed overall survival was 70.5 % (95 % CI 68.4–72.6) and relative survival 90.8 % (95 % CI 88.2–93.7).</div><div>Treatment data were registered in 1,948 cases and 97.5 % (1,900) had a curative intent, whereof 88.5 % had surgery, 7.3 % radiotherapy, and 4.2 % combination treatment. Recurrences were registered in 5.6 % (48.6 % local, 42.1 % regional) whereof 15.9 % after three years. Stage I recurred after median 17 (IQR 9–28) months whereas stage II and III after 10 months (7–17 and 9–13, respectively). Advanced age (p &lt; 0.001), poor performance status (p &lt; 0.001), male sex (p = 0.002), high stage (p = 0.041), and only radiotherapy (p = 0.007) remained as independent prognostic factors for mortality.</div></div><div><h3>Conclusion</h3><div>Females had higher incidence increase than males. Advanced age, poor performance status, male sex, advanced disease, and radiotherapy only were independent prognostic factors for mortality.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107818"},"PeriodicalIF":3.9,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot study of a digital workflow for navigated tumor bed marking to reduce clinical target volume during adjuvant radiotherapy for oral squamous cell carcinoma","authors":"Frederik Holdorf ,&nbsp;Henning Schliephake ,&nbsp;Kathi Goldstein ,&nbsp;Lennart Johannes Gruber ,&nbsp;Phillipp Brockmeyer ,&nbsp;Martin Leu ,&nbsp;Stefan Rieken ,&nbsp;Boris Schminke","doi":"10.1016/j.oraloncology.2025.107820","DOIUrl":"10.1016/j.oraloncology.2025.107820","url":null,"abstract":"<div><h3>Purpose</h3><div>The treatment of advanced-stage oral squamous cell carcinoma (OSCC) often requires adjuvant radiotherapy to improve the survival rate. Accurately defining the clinical target volume (CTV) is critical for radiation treatment to maximize the radiation dose and minimize negative side effects. However, precise planning remains difficult because of postoperative anatomical changes, which may lead to oversized volumes with increased collateral damage to adjacent tissues. The aim of this study is to suggest a digital planning algorithm to improve the precision of CTV definition.</div></div><div><h3>Methods</h3><div>In this pilot study, intraoperative digital tracings of tumor resection margins were located in the preoperative computed tomography (CT) datasets of ten patients with advanced OSCC using the Brainlab Curve navigation system. OSCCs of the tongue were excluded from this analysis because of their unique anatomical features. The preoperative scans with digital tracings were aligned with the postoperative scans to identify the desired CTV. The digitally navigated CTVs were compared with the CTVs resulting from conventional planning.</div></div><div><h3>Results</h3><div>Our findings demonstrated that the digital workflow can be easily integrated into the surgical procedure and provides a straightforward and reproducible method to achieve a statistically significant average reduction of 25.71% in the CTV.</div></div><div><h3>Conclusion</h3><div>This innovative approach to digital tracing of the resection margins in postoperative CT scans significantly increases the precision of CTV planning. Clinical studies will be needed to test the oncological safety compared to conventional planning algorithms and the potential for improved outcomes with respect to side effects and quality of life.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107820"},"PeriodicalIF":3.9,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-derived 3D organoid platform for functional assessment of GPC3-targeted CAR T cell cytotoxic activity in head and neck squamous cell carcinoma","authors":"Han-Na Yoon ,&nbsp;Jin-ha Kim ,&nbsp;Doeon Gu ,&nbsp;Jonghyun Lee ,&nbsp;Soo Yoon Kim ,&nbsp;Hye Jin Kim ,&nbsp;Jaehyeon Jeong ,&nbsp;Dongkwan Shin ,&nbsp;Yuh-Seog Jung ,&nbsp;Man Ki Chung ,&nbsp;Sang-Jin Lee ,&nbsp;Sung Yong Choi","doi":"10.1016/j.oraloncology.2025.107814","DOIUrl":"10.1016/j.oraloncology.2025.107814","url":null,"abstract":"<div><h3>Background</h3><div>Head and neck squamous cell carcinoma (HNSCC) remains a therapeutic challenge owing to its marked heterogeneity and limited immunotherapy efficacy, underscoring the need for improved therapeutic strategies and preclinical systems supporting clinical translation.</div></div><div><h3>Method</h3><div>We established a simplified and optimized 3D head and neck cancer organoid (HNCO)–chimeric antigen receptor (CAR) T cell co-culture platform that maintains uniform spheroid architecture (&gt;500 μm) to recapitulate physiological hypoxia while preserving the tumor secretome. CAR T cell cytotoxic activity was assessed through multimodal readouts—structural disruption, ATP-based viability, and granzyme B secretion. Following initial organoid seeding, the workflow proceeded without physical manipulation, enabling concurrent multimodal assessment of CAR T cell activity from a single co-culture.</div></div><div><h3>Results</h3><div>Analysis of The Cancer Genome Atlas (TCGA) data revealed that high glypican-3 (GPC3) expression was associated with poor survival in patients with HNSCC. We generated GPC3-targeted CAR T (GPC3-CAR T) cells. Using our co-culture platform, we evaluated the cytotoxic activity of GPC3-CAR T cells against five HNCOs harboring diverse genetic alterations and variable GPC3 expression. Organoids with high or moderate GPC3 expression consistently exhibited structural disintegration, reduced viability, and increased granzyme B secretion, whereas GPC3-low organoids showed heterogeneous responses.</div></div><div><h3>Conclusions</h3><div>This proof-of-concept study introduces a patient-derived 3D organoid platform for functional assessment of CAR T cell cytotoxic activity in HNSCC. Our findings suggest that GPC3-CAR T therapy may be clinically applicable to subsets of patients with HNSCC, while emphasizing the need for functional validation to account for interpatient heterogeneity in clinical translation.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107814"},"PeriodicalIF":3.9,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145725145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTCH1 loss promotes chemo and radio-resistance in head and neck cancer","authors":"Mushfiq H. Shaikh ,&nbsp;Walid Gazala ,&nbsp;Cindy Zeng ,&nbsp;Mahdi Farzad Naimi ,&nbsp;Matthew Cecchini ,&nbsp;Amir Karimi ,&nbsp;Halema Khan ,&nbsp;Krista Joris ,&nbsp;Shengjie Ying ,&nbsp;Harrison Pan ,&nbsp;Mohd Wessam Al Jawhri ,&nbsp;David A. Palma ,&nbsp;Joe S. Mymryk ,&nbsp;Peter YF. Zeng ,&nbsp;John W. Barrett ,&nbsp;Anthony C. Nichols","doi":"10.1016/j.oraloncology.2025.107815","DOIUrl":"10.1016/j.oraloncology.2025.107815","url":null,"abstract":"<div><h3>Introduction</h3><div>Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with over 700,000 new cases diagnosed annually. HPV-associated HNSCC patients generally respond well to standard therapies; however, about 15–20 % experience recurrence, while the rate is approximately 50 % in non-HPV-associated HNSCC. Identifying biomarkers for treatment failure is crucial for optimizing treatment strategies. Our lab’s whole genome sequencing (WGS) data has identified <em>NOTCH1</em> mutations as enriched in recurrent HPV-positive HNSCC cases. This study investigates whether <em>NOTCH1</em> deletion confers treatment resistance in both HPV-positive and HPV-negative HNSCC models.</div></div><div><h3>Methods</h3><div>Four HPV-positive (HPV+) HNSCC cell lines (UWO23, UWO37, UMSCC47, and 93VU147) and two HPV-negative (HPV−) HNSCC cell lines (FaDu and Cal27) were examined. We used siRNA to knock down <em>NOTCH1</em> expression, confirmed by qPCR, and then used CRISPR editing to generate stable <em>NOTCH1</em> knockout (KO) cells. The knockout was validated by real-time qPCR and western blotting. Cell viability, clonogenicity, and invasiveness were then evaluated through viability, colony formation, and invasion assays.</div></div><div><h3>Results</h3><div>The siRNA-mediated <em>NOTCH1</em> knockdown increased cellular proliferation in both HPV+ and HPV− HNSCC lines, with similar effects observed in CRISPR-edited <em>NOTCH1</em>-KO cells. Colony formation and invasion assays demonstrated higher aggression and invasiveness in <em>NOTCH1</em>-KO cells compared to non-targeting controls (NTC). IC50 analysis showed that <em>NOTCH1</em>-KO cells exhibited enhanced cisplatin resistance in both HPV+ and HPV− lines, with increased radiation resistance also observed in <em>NOTCH1</em>-KO cells.</div></div><div><h3>Conclusion</h3><div>Our findings indicate that <em>NOTCH1</em> loss in both HPV+ and HPV− HNSCC cell lines leads to increased aggressiveness, clonogenicity, invasiveness, and resistance to chemotherapy and radiation. This suggests that <em>NOTCH1</em> loss may be a potential biomarker for identifying HNSCC patients at higher risk of treatment failure, supporting a more personalized, intensive therapeutic approach.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107815"},"PeriodicalIF":3.9,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated geriatric assessment and intervention in the head and neck oncology care pathway reduces adverse events and does not affect survival","authors":"Beniamino Vincenzoni Padovan ,&nbsp;Marleen Beenker ,&nbsp;Johannes A. Langendijk ,&nbsp;Hans Paul van der Laan ,&nbsp;Boukje A.C. van Dijk ,&nbsp;Geertrudia H. de Bock ,&nbsp;Boudewijn E.C. Plaat ,&nbsp;Pauline de Graeff ,&nbsp;Suzanne Festen ,&nbsp;Gyorgy B. Halmos","doi":"10.1016/j.oraloncology.2025.107811","DOIUrl":"10.1016/j.oraloncology.2025.107811","url":null,"abstract":"<div><h3>Objective</h3><div>The number of older/frail patients with head and neck cancer (HNC) is increasing. They are more frail compared to patients with other malignancies. Therefore, geriatric care is increasingly integrated into the HNC care pathway. The aim of this study was to investigate how integrated geriatric care affects treatment outcomes in HNC patients irrespective of treatment intention.</div></div><div><h3>Methods</h3><div>This retrospective study compared treatment-related adverse outcomes (grade ≥ 2 Clavien-Dindo surgical complications and grade ≥ 2 CTCAE (chemo)radiotoxicity), and one-year mortality in two patient cohorts. In the first cohort (2014–2016), geriatric screening was only observational i.e. without intervention. In the second cohort (2019–2020), a complete geriatric pathway was integrated into the oncological care pathway, including an onco-geriatric MDT (multidisciplinary team meeting), referral to the geriatrician with intervention, if needed. Multivariable logistic regression analysis was performed to identify factors associated with adverse events and one-year mortality, including the cohort period.</div></div><div><h3>Results</h3><div>This study included 640 patients; 369 from the first cohort and 271 from the second cohort. The second cohort showed significantly fewer adverse events (34.6 %) compared to the first (65.4 %) (OR 0.41; 95 % CI 0.27–0.63: p &lt; 0.001). Reductions were seen in surgical complications (OR 0.57; 95 % CI 0.32–1.01) as well as (chemo)radiotoxicity (OR 0.39; 95 % CI 0.20–0.76). No significant differences were observed in one-year mortality (OR 0.88; CI 0.59–1.48). Adverse events were significantly linked to malnutrition, advanced tumor stage and concomitant radiotherapy treatment.</div></div><div><h3>Conclusion</h3><div>Integration of geriatric care in the HNC pathway reduces treatment-related adverse events, without altering one-year mortality.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107811"},"PeriodicalIF":3.9,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer","authors":"Sholem Hack ,&nbsp;Rebecca Attal ,&nbsp;Karin Geva ,&nbsp;Armin Farzad ,&nbsp;Shibli Alsleibi ,&nbsp;Naseem Saleh ,&nbsp;Ben Gvili ,&nbsp;David Yogev ,&nbsp;David Shahal ,&nbsp;Benyamin Meir Kaminer ,&nbsp;Eric Remer","doi":"10.1016/j.oraloncology.2025.107813","DOIUrl":"10.1016/j.oraloncology.2025.107813","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the quality of online information about human papillomavirus (HPV)–associated oropharyngeal cancer generated by a large language model with content retrieved from conventional web search and authoritative guideline-based sources.</div></div><div><h3>Methods</h3><div>Twenty high-volume patient search queries were identified using global Google Trends data. For each question, responses were obtained from GPT-4 (OpenAI), the highest-ranked non-sponsored Google Search result, and leading governmental or guideline-based websites. Responses were anonymized and evaluated in a blinded manner by seven otolaryngology specialists and ten adult laypersons. Experts assessed accuracy, clarity, completeness, relevance, and usefulness; laypersons rated clarity, trustworthiness, and usefulness. Comparative analyses were performed using Friedman and Bonferroni-corrected Wilcoxon signed-rank tests, with inter-rater agreement estimated using intraclass correlation coefficients (ICC)</div></div><div><h3>Results</h3><div>ChatGPT-generated responses received higher mean ratings than Google Search across all domains for both rater cohorts (p &lt; 0.001 for all comparisons). Experts rated GPT-4 and guideline-based content similarly for accuracy, completeness, and usefulness, while GPT-4 scored significantly higher for clarity and relevance (p &lt; 0.01). Laypersons rated GPT-4 responses highest across all domains, with median scores of 5 versus 4 for the other sources. Inter-rater agreement was modest for subjective domains.</div></div><div><h3>Conclusion</h3><div>ChatGPT-generated information on HPV-associated oropharyngeal cancer matched the accuracy and completeness of authoritative guideline-based content and demonstrated significantly greater clarity and relevance, while outperforming conventional web search results. LLMs may help improve accessibility and consistency of online patient education when implemented with expert oversight, transparent sourcing, and ongoing quality monitoring.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107813"},"PeriodicalIF":3.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145682466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial","authors":"Wen-Jie Wu ,&nbsp;Pu-Gen An ,&nbsp;Zi-Qi Zhang ,&nbsp;Li-Hang Shen ,&nbsp;Jian-Yun Zhang ,&nbsp;Yan Chen ,&nbsp;Ming-Wei Huang ,&nbsp;Shu-Ming Liu ,&nbsp;Jie Yao ,&nbsp;Jie Zhang","doi":"10.1016/j.oraloncology.2025.107809","DOIUrl":"10.1016/j.oraloncology.2025.107809","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to evaluate the antitumor effect and safety of neoadjuvant chemotherapy plus tislelizumab (a programmed death-1 inhibitor) for the treatment of resectable locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC).</div></div><div><h3>Methods</h3><div>Eligible patients with stage III-IV LAOOPSCC were treated with two cycles of tislelizumab (200 mg), albumin-bound paclitaxel (260 mg/m²), and cisplatin (60–75 mg/m²) with a three-week interval between each cycle; this treatment was followed by surgery and adjuvant radiotherapy or concurrent chemoradiotherapy. The primary endpoints were the major pathological response (MPR) rate and safety.</div></div><div><h3>Results</h3><div>Between March 2022 and June 2023, a total of 82 patients were eligible and completed two cycles of neoadjuvant therapy; 78 patients underwent imaging evaluation, and 73 underwent surgery and pathological response evaluation. Forty patients underwent de-escalation surgery for the primary tumor. Orbital floor resection was avoided in 1 patient, mandibulectomy was avoided in 5 patients, and near-total glossectomy or total glossectomy was avoided in 32 patients. An objective response rate of 67.9 % and an MPR rate of 60.3 % were achieved, with 34.2 % of patients achieving a pathological complete response. With a median follow-up time of 24 months, the two-year overall survival rate was 84.4 %, and the two-year event-free survival rate was 76.7 %. Treatment-related adverse events of grade 3 or 4 occurred in 11 patients (13.4 %) during the neoadjuvant therapy.</div></div><div><h3>Conclusions</h3><div>Neoadjuvant tislelizumab plus chemotherapy for LAOOPSCC achieved a high pathological response rate and favorable survival metrics with an acceptable safety profile.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107809"},"PeriodicalIF":3.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145682467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining surveillance in surgically treated HPV(+)OPSCC: The path to Risk-Adapted strategies","authors":"Jiaqian Wu,&nbsp;Jianning Zhang,&nbsp;Jiachuan Lin,&nbsp;Yan Huo","doi":"10.1016/j.oraloncology.2025.107812","DOIUrl":"10.1016/j.oraloncology.2025.107812","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107812"},"PeriodicalIF":3.9,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}